Photo of AstraZeneca logo from LinkedIn
May 20, 2024, 11:14
AstraZeneca announces plans for a $1.5 billion manufacturing facility in Singapore for ADCs
AstraZeneca shared on LinkedIn:
“We are excited to announce our plans for a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs). ADCs are a class of drugs designed as a targeted therapy for treating cancer. .
This new facility will further enhance our world-class supply chain. The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be designed to emit zero carbon from its first day of operations and will be the first end-to-end ADC production site in our global manufacturing and supply network.”
Source: AstraZeneca/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 09:55
Nov 21, 2024, 09:28
Nov 21, 2024, 09:23
Nov 21, 2024, 09:04
Nov 21, 2024, 06:49